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should not) know, based on personal and unsubstantiated physi-
cian biases.
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REPLY
We do appreciate Ms. Salberg’s concern regarding the best treatment
for patients with hypertrophic obstructive cardiomyopathy. As the
representative of the Hypertrophic Cardiomyopathy Association, Ms.
Salberg must keep a close eye on what should be recommended to
those numerous sufferers from this inherited disease.
Ms. Salberg states that the “counterpoint” we offered in the
Journal of the American College of Cardiology is brief and incomplete
(1). The first statement is correct as it was purposely reduced to the
minimum in order to make it more readable. The second statement
(incomplete) is debatable.
The statement that the investigators have “omitted a treatment
strategy from their Figure 1 (pg. 2055) (i.e., septal myectomy),
which has, in fact, provided symptomatic benefits and enhanced
longevity to thousands of HCM patients worldwide for over 45
years” is, of course, part of the strategy behind the “counterpoint.”
We were asked to make the point for the nonsurgical option.
We do believe that alcohol ablation should be the first treatment
of choice for patients with hypertrophic obstructive cardiomyop-
athy who are not well on medical treatment. As Ms. Salberg
correctly states, the surgical option has been used for 45 years,
although much less over the last 10 years when alcohol ablation
became available. According to the published literature, approxi-
mately 3,000 patients have been treated surgically over those
45 years. In contrast, more than 4,000 patients have been con-
signed to the much less invasive strategy of alcohol ablation, which,
as most investigators agree, provides similar symptomatic relief. As
no randomized trial to compare both treatment options has ever
been conducted, it is difficult to justify the significantly higher
morbidity and probably also mortality of the surgical technique as
a first option.
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